New phase 3b data showed that, with just eight weeks of treatment, Mavyret could cure HCV patients with compensated cirrhosis.
Who wants drug prices in ads? Older people, that’s who.
Merck’s Keytruda is looking to beat its immuno-oncology rivals into yet another market, and it just posted the data that could get the job done.
Mitsubishi Tanabe Pharma is looking for ALS stories. Not patient stories, but rather the stories—and art and video creations—of teen caregivers.
Johnson & Johnson's Janssen is using Twitter to get the word out about the link between Type 2 diabetes and cardiovascular risks.
Tecentriq is on its way to becoming the first immuno-oncology drug with an approval in triple negative breast cancer, and that path just got shorter.
When does CMI/Compas exec Paul Kallukaran think pharma should start working machine learning in their marketing strategies? "Yesterday."
Some critics said the abnormal trends in key CV biomarkers in the placebo arm has compromised the otherwise exciting data.
Merck just advanced the Keytruda-Opdivo immuno-oncology rivalry into a brand-new arena.
The FDA has bestowed its priority review designation on Lynparza, setting it up for a billion-dollar opportunity—and a leg up on its PARP rivals.
